Baritinib is a selective Janus kinase (JAK) 1/2 inhibitor that inhibits intracellular signaling of various inflammatory cytokines (such as IL-6 and IFN - γ) by blocking the JAK-STAT signaling pathway, thereby reducing inflammation and immune-mediated tissue damage.

1、 Drug name

Baricitinib (trade name: Olumiant).

2、 Indications

1. Adults with moderate to severe active rheumatoid arthritis (those with insufficient or intolerant response to DMARDs).

2. Adults and children aged 2 and above with moderate to severe atopic dermatitis (those requiring systemic treatment).

3. Severe alopecia areata in adults.

4. Children over 2 years old with active juvenile idiopathic arthritis (those who have insufficient response to traditional or biological DMARDs).

3、 Specifications and characteristics

2mg、4mg、 Tablets.

4、 Main components

Each tablet contains 2mg or 4mg of Baricitinib, respectively..

5、 Usage and dosage

1. Conventional dosage:

Rheumatoid arthritis/atopic dermatitis/alopecia areata: Adults are recommended to take 4mg once daily, and high-risk patients (such as ≥ 65 years old) are recommended to take 2mg once daily.

Pediatric atopic dermatitis/juvenile arthritis: 4mg once daily for those weighing ≥ 30kg, 2mg once daily for those weighing 10-30kg.

2. Medication method: Oral administration at a fixed time daily, can be taken with food or on an empty stomach.

6、 Dose adjustment

1. Renal insufficiency (CrCl30-60mL/min): 2mg/day for adults and halved for children.

2. Use strong OAT3 inhibitors (such as probenecid): dose halved.

3. After insufficient or stable treatment response: dosage can be adjusted (4mg) ↔ 2mg)。

7、 Medication precautions

1. Missed medication: If missed, it should be taken as soon as possible. If it is close to the next medication time, skip it and do not double the medication.

2. Vomiting: If vomiting occurs after taking medication, there is no need to take it again. Follow the original plan for the next dose.

3. Children's medication: For those who cannot swallow the whole tablet, it can be dispersed in water for administration.

8、 Medication for special populations

1. Pregnant women: Prohibited, effective contraception is required during the medication period and one week after discontinuation.

2. Breastfeeding period: Prohibited.

3. Elderly people (≥ 75 years old): Limited data, use with caution.

4. Patients with liver damage: Prohibited for severe liver damage.

9、 Adverse reactions

1. Common: elevated LDL (26%), upper respiratory tract infection (16.9%), headache (5.2%).

2. Serious risks: infection (including tuberculosis), venous thrombosis, malignant tumors, gastrointestinal perforation.

10、 Contraindications

1. People who are allergic to ingredients.

2. Pregnancy period.

3. Active tuberculosis/severe infection.

11、 Drug interactions

1. Immunosuppressants: Avoid using biologics/other JAK inhibitors in combination.

2. OAT3 inhibitors: If probenecid increases blood drug concentration, it needs to be reduced.

3. Live vaccine: Avoid vaccination during medication.

12、 Storage method

Not explicitly stated, it is recommended to store in a dark and dry place. Please refer to the packaging instructions for details.

Baricitinibinformation